• Nutra Pharma posted a net loss of $459,675 for the quarter ended March 31, 2026, narrowing 67.28% from a year earlier.
• Net sales fell 63.17% to $27,246, reflecting dietary supplement lines transitioned to Avini Health and lower private-label order volumes.
• Gross profit dropped to $18,975, cutting gross margin by 14.2 percentage points to 39.36% on lower sales volume and relatively fixed fulfillment costs.
• Operating expenses eased 2.62% to $398,224, while interest expense rose 2.62% to $100,362 on higher amortization of loan discounts.
• Nutra Pharma recorded a $140,500 gain on debt settlement, while highlighting expanded online marketing since October 2025 and Pet Pain-Away’s placement on Chewy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutra Pharma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-026420), on May 29, 2026, and is solely responsible for the information contained therein.